CytomX Therapeutics reported positive clinical data for Varseta-M, its experimental therapy for colorectal cancer treatment. The drug achieved an overall response rate of 32% and a median progression-free survival of 7.1 months at the high dose of 10 mg/kg in the trial.
The clinical results represent encouraging efficacy signals for Varseta-M in treating colorectal cancer patients. The 32% overall response rate and 7.1-month median progression-free survival at the 10 mg/kg dose level suggest potential therapeutic benefit, though longer-term safety and durability data will be critical for regulatory advancement.